Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Licenses ImmunoGen’s ADC Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novartis Licenses ImmunoGen’s ADC Technology

ImmunoGen eligible for milestones and royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImmunoGen and Novartis have entered a licensing agreement under which Novartis has the exclusive right to use the company’s ADC technology to develop anticancer therapeutics for an undisclosed target.
 
This is the second license agreement between the companies. For each license, ImmunoGen receives an upfront payment and is entitled to receive milestones potentially totaling $200 million, plus royalties on sales of any resulting products. Novartis is responsible for the development, manufacture and marketing of any products resulting from the license.
 
“We believe the therapies Novartis is developing with our ADC technology have the potential to make an important difference for patients,” said Daniel Junius, president and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics